Entera Bio Ltd. (ENTX)
USD 1.62
(-1.22%)
USD 1.62
(-1.22%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.76 Million USD | -10.38% |
| 2022 | 13.12 Million USD | -49.49% |
| 2021 | 25.98 Million USD | 153.24% |
| 2020 | 10.26 Million USD | -38.56% |
| 2019 | 16.7 Million USD | 25.2% |
| 2018 | 13.34 Million USD | 0.47% |
| 2017 | 13.27 Million USD | 111.23% |
| 2016 | 6.28 Million USD | 128.83% |
| 2015 | 2.74 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 10.23 Million USD | -12.97% |
| 2024 Q2 | 10.03 Million USD | -1.99% |
| 2023 Q4 | 11.76 Million USD | 37.36% |
| 2023 FY | 11.76 Million USD | -10.38% |
| 2023 Q1 | 11.6 Million USD | -11.59% |
| 2023 Q2 | 10.44 Million USD | -10.0% |
| 2023 Q3 | 8.56 Million USD | -18.0% |
| 2022 Q1 | 22.31 Million USD | -14.14% |
| 2022 Q4 | 13.12 Million USD | -15.53% |
| 2022 Q2 | 19.08 Million USD | -14.45% |
| 2022 FY | 13.12 Million USD | -49.49% |
| 2022 Q3 | 15.54 Million USD | -18.59% |
| 2021 Q2 | 28.93 Million USD | 56.2% |
| 2021 FY | 25.98 Million USD | 153.24% |
| 2021 Q1 | 18.52 Million USD | 80.54% |
| 2021 Q4 | 25.98 Million USD | -10.75% |
| 2021 Q3 | 29.11 Million USD | 0.61% |
| 2020 Q3 | 8.78 Million USD | -23.4% |
| 2020 FY | 10.26 Million USD | -38.56% |
| 2020 Q1 | 15.18 Million USD | -9.1% |
| 2020 Q2 | 11.46 Million USD | -24.51% |
| 2020 Q4 | 10.26 Million USD | 16.88% |
| 2019 Q3 | 7.32 Million USD | -19.09% |
| 2019 Q2 | 9.05 Million USD | -20.64% |
| 2019 Q1 | 11.4 Million USD | -14.51% |
| 2019 FY | 16.7 Million USD | 25.2% |
| 2019 Q4 | 16.7 Million USD | 128.09% |
| 2018 Q1 | - USD | -100.0% |
| 2018 FY | 13.34 Million USD | 0.47% |
| 2018 Q3 | 15.14 Million USD | 80.55% |
| 2018 Q2 | 8.39 Million USD | 0.0% |
| 2018 Q4 | 13.34 Million USD | -11.93% |
| 2017 Q1 | - USD | -100.0% |
| 2017 Q2 | 3.65 Million USD | 0.0% |
| 2017 FY | 13.27 Million USD | 111.23% |
| 2017 Q4 | 13.27 Million USD | 214.64% |
| 2017 Q3 | 4.22 Million USD | 15.36% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q4 | 6.28 Million USD | 0.0% |
| 2016 FY | 6.28 Million USD | 128.83% |
| 2015 FY | 2.74 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 99.209% |
| Alkermes plc | 2.13 Billion USD | 99.449% |
| Agenus Inc. | 313.91 Million USD | 96.252% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 99.693% |
| Aptorum Group Limited | 20.64 Million USD | 42.999% |
| Ardelyx, Inc. | 297.57 Million USD | 96.046% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 98.463% |
| Bicycle Therapeutics plc | 595.34 Million USD | 98.024% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | 84.037% |
| ChromaDex Corporation | 54.96 Million USD | 78.595% |
| Chimerix, Inc. | 212.77 Million USD | 94.471% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | 58.387% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 97.332% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 99.472% |
| Precision BioSciences, Inc. | 159.78 Million USD | 92.637% |
| Dyadic International, Inc. | 8.21 Million USD | -43.14% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | 62.933% |
| Fortress Biotech, Inc. | 167.52 Million USD | 92.977% |
| Lantern Pharma Inc. | 43.64 Million USD | 73.045% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | 92.708% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | 18.899% |
| Incyte Corporation | 6.78 Billion USD | 99.827% |
| IO Biotech, Inc. | 150.71 Million USD | 92.194% |
| Jaguar Health, Inc. | 50.76 Million USD | 76.824% |
| Novavax, Inc. | 1.85 Billion USD | 99.366% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 96.907% |
| Opthea Limited | 188.79 Million USD | 93.768% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 98.588% |
| ContextLogic Inc. | 423 Million USD | 97.219% |
| MiMedx Group, Inc. | 239.04 Million USD | 95.078% |
| Pyxis Oncology, Inc. | 173.72 Million USD | 93.228% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -127.576% |
| NextCure, Inc. | 129.41 Million USD | 90.909% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | 78.192% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | 67.968% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | 63.577% |
| Vaxcyte, Inc. | 1.4 Billion USD | 99.164% |
| PDS Biotechnology Corporation | 59.39 Million USD | 80.19% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 98.163% |
| Pharming Group N.V. | 462.85 Million USD | 97.458% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | 69.584% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 98.128% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 37.829% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 37.829% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 92.883% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | 74.021% |
| Acelyrin, Inc. | 742.69 Million USD | 98.416% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -78.622% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -83.742% |
| Summit Therapeutics Inc. | 202.94 Million USD | 94.203% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | 84.181% |
| Senti Biosciences, Inc. | 119.48 Million USD | 90.153% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | 94.848% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | 93.004% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -42.382% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -146.451% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 97.492% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | 90.485% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 95.721% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 97.512% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -16.428% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | 94.515% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -939.165% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 97.157% |
| Immix Biopharma, Inc. | 19.92 Million USD | 40.954% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 96.82% |
| MEI Pharma, Inc. | 41.37 Million USD | 71.565% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 63.695% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 96.548% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | 89.964% |
| Fortress Biotech, Inc. | 167.52 Million USD | 92.977% |
| Precigen, Inc. | 151.04 Million USD | 92.211% |
| Clearside Biomedical, Inc. | 34.01 Million USD | 65.415% |
| AlloVir, Inc. | 190.79 Million USD | 93.834% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 96.875% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 97.676% |
| ImmuCell Corporation | 43.8 Million USD | 73.144% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 98.188% |
| Onconetix, Inc. | 88.82 Million USD | 86.754% |
| PureTech Health plc | 693.97 Million USD | 98.305% |
| VYNE Therapeutics Inc. | 97.68 Million USD | 87.956% |
| Elevation Oncology, Inc. | 89.09 Million USD | 86.794% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -89.697% |
| Seer, Inc. | 436.26 Million USD | 97.303% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | 85.582% |
| Innoviva, Inc. | 1.24 Billion USD | 99.054% |
| Aadi Bioscience, Inc. | 132.42 Million USD | 91.116% |
| ESSA Pharma Inc. | 149.12 Million USD | 92.11% |
| GlycoMimetics, Inc. | 45.31 Million USD | 74.038% |
| GT Biopharma, Inc. | 14.1 Million USD | 16.614% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 96.179% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 95.132% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 97.507% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | 76.793% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | 87.643% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -1762.765% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 97.923% |
| Aptose Biosciences Inc. | 12.92 Million USD | 8.958% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | 46.799% |
| Soligenix, Inc. | 9.79 Million USD | -20.084% |
| Century Therapeutics, Inc. | 360.69 Million USD | 96.738% |
| Kura Oncology, Inc. | 448.93 Million USD | 97.379% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 95.677% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | 31.975% |
| Ocean Biomedical, Inc. | 110.91 Million USD | 89.392% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | 94.265% |
| Autolus Therapeutics plc | 375.38 Million USD | 96.866% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 95.325% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 96.688% |
| Eterna Therapeutics Inc. | 49.13 Million USD | 76.054% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 98.22% |
| GRI Bio, Inc. | 2.95 Million USD | -298.004% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -10.936% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | 93.1% |
| IGM Biosciences, Inc. | 423.41 Million USD | 97.221% |
| INmune Bio, Inc. | 57 Million USD | 79.36% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 94.713% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 85.984% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 54.952% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -70.924% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | 84.36% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | 92.011% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 92.891% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 98.131% |
| Verastem, Inc. | 149.71 Million USD | 92.142% |
| Abeona Therapeutics Inc. | 64 Million USD | 81.618% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 97.703% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | 92.383% |
| Histogen Inc. | 19.07 Million USD | 38.316% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | 48.058% |
| Surrozen, Inc. | 46.08 Million USD | 74.468% |
| Organovo Holdings, Inc. | 6.34 Million USD | -85.305% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -173.057% |
| Ovid Therapeutics Inc. | 144.02 Million USD | 91.831% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 0.314% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | 84.369% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -38.099% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 96.759% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | 34.98% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 97.26% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | 6.714% |
| Apollomics, Inc. | 55.38 Million USD | 78.759% |
| Amarin Corporation plc | 831.68 Million USD | 98.585% |
| Mesoblast Limited | 669.15 Million USD | 98.242% |
| Turnstone Biologics Corp. | 112.81 Million USD | 89.571% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 97.957% |
| Synaptogenix, Inc. | 31.11 Million USD | 62.187% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | 3.439% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 97.853% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -100.349% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -60.174% |
| Exelixis, Inc. | 2.94 Billion USD | 99.6% |
| Better Therapeutics, Inc. | 22.94 Million USD | 48.721% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 96.773% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 98.508% |
| NLS Pharmaceutics AG | 1.84 Million USD | -537.103% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -47.456% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 19.939% |
| Gritstone bio, Inc. | 177.76 Million USD | 93.382% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 87.665% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | 34.135% |
| Avid Bioservices, Inc. | 336.55 Million USD | 96.504% |
| Insmed Incorporated | 1.32 Billion USD | 99.115% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -22.191% |
| MediWound Ltd. | 66.45 Million USD | 82.297% |
| OmniAb, Inc. | 401.98 Million USD | 97.073% |
| Alector, Inc. | 621.82 Million USD | 98.108% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 96.719% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -118.762% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 79.248% |
| Zai Lab Limited | 1.03 Billion USD | 98.865% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 97.541% |
| Aura Biosciences, Inc. | 255.07 Million USD | 95.388% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 98.431% |
| Immunic, Inc. | 54.29 Million USD | 78.333% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 95.581% |
| Veracyte, Inc. | 1.13 Billion USD | 98.966% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | 0.489% |
| FibroGen, Inc. | 423.52 Million USD | 97.222% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -234.899% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -148.385% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -116.687% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 99.897% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -33.617% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 97.726% |
| TG Therapeutics, Inc. | 329.58 Million USD | 96.43% |
| Galecto, Inc. | 38.22 Million USD | 69.223% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 58.973% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 99.73% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 95.002% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | 52.641% |
| XBiotech Inc. | 227.24 Million USD | 94.823% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 87.665% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | 91.75% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 95.885% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | 90.799% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 96.92% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 99.211% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 96.775% |
| Vaxxinity, Inc. | 44.35 Million USD | 73.474% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 97.724% |
| Gain Therapeutics, Inc. | 18.6 Million USD | 36.779% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 96.143% |
| NexImmune, Inc. | 8.59 Million USD | -36.899% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -9.797% |
| Marker Therapeutics, Inc. | 17.12 Million USD | 31.309% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.964% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | 46.888% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -2899.248% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | 93.212% |
| Ainos, Inc. | 31.84 Million USD | 63.052% |
| Pluri Inc. | 39.52 Million USD | 70.236% |
| Prothena Corporation plc | 696.38 Million USD | 98.311% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 95.837% |
| Celularity Inc. | 143.88 Million USD | 91.824% |
| Rallybio Corporation | 115.62 Million USD | 89.824% |
| Cue Biopharma, Inc. | 61.53 Million USD | 80.879% |
| MeiraGTx Holdings plc | 458.16 Million USD | 97.432% |
| Omeros Corporation | 378.26 Million USD | 96.89% |
| Humacyte, Inc. | 128.22 Million USD | 90.825% |
| Immunocore Holdings plc | 597 Million USD | 98.029% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | 62.363% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | 82.832% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 98.879% |
| CalciMedica, Inc. | 12.18 Million USD | 3.447% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 95.362% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | 93.116% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 96.217% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 97.919% |
| Pulmatrix, Inc. | 33.95 Million USD | 65.354% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | 56.66% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | 91.648% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 99.096% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | 90.963% |
| Cytokinetics, Incorporated | 824.31 Million USD | 98.573% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 44.302% |
| Nutriband Inc. | 7.51 Million USD | -56.509% |
| Protara Therapeutics, Inc. | 78.95 Million USD | 85.099% |
| Vor Biopharma Inc. | 209.82 Million USD | 94.393% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 99.837% |
| Evogene Ltd. | 51.1 Million USD | 76.977% |
| ProKidney Corp. | 420.55 Million USD | 97.202% |
| Applied Therapeutics, Inc. | 54.83 Million USD | 78.544% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -23.578% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 97.847% |
| CorMedix Inc. | 82.05 Million USD | 85.663% |
| BioLineRx Ltd. | 63.92 Million USD | 81.596% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 97.078% |
| Galectin Therapeutics Inc. | 28.2 Million USD | 58.28% |
| Atai Life Sciences N.V. | 293.47 Million USD | 95.991% |
| Renovaro Biosciences Inc. | 163.12 Million USD | 92.788% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | 90.767% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 97.907% |
| Sagimet Biosciences Inc. | 96.71 Million USD | 87.836% |
| MediciNova, Inc. | 66.26 Million USD | 82.247% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | 86.623% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -163.649% |
| GeoVax Labs, Inc. | 9.28 Million USD | -26.734% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 98.0% |
| Biomea Fusion, Inc. | 199.92 Million USD | 94.115% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 99.382% |
| Mereo BioPharma Group plc | 66.49 Million USD | 82.308% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 97.575% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 98.08% |
| Absci Corporation | 234.48 Million USD | 94.983% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -60.834% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 96.539% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | 92.873% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 97.765% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 95.763% |
| Allakos Inc. | 243.61 Million USD | 95.171% |
| Imunon, Inc. | 21.91 Million USD | 46.323% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 95.435% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 98.107% |
| BioAtla, Inc. | 119.65 Million USD | 90.168% |
| NLS Pharmaceutics AG | 1.84 Million USD | -537.103% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -265.373% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 98.17% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | 87.736% |
| XOMA Corporation | 234.3 Million USD | 94.979% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | 94.682% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 90.651% |
| aTyr Pharma, Inc. | 122.06 Million USD | 90.362% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | 92.356% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 97.972% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 97.601% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | 89.35% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | 22.382% |
| Akari Therapeutics, Plc | 4.35 Million USD | -170.149% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 30.946% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 99.321% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -281.487% |
| UroGen Pharma Ltd. | 178.31 Million USD | 93.402% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 97.501% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -2017.092% |
| Orgenesis Inc. | 14.55 Million USD | 19.152% |
| GH Research PLC | 226.3 Million USD | 94.801% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | 78.489% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | 89.049% |
| Xencor, Inc. | 952.69 Million USD | 98.765% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -51.148% |
| Replimune Group, Inc. | 487.72 Million USD | 97.588% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -45.767% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 98.186% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -281.487% |
| Portage Biotech Inc. | 7.77 Million USD | -51.241% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -163.649% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 95.752% |
| OncoCyte Corporation | 74.89 Million USD | 84.291% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -478.631% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -103.313% |
| Purple Biotech Ltd. | 44.3 Million USD | 73.444% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | 65.525% |
| scPharmaceuticals Inc. | 94.47 Million USD | 87.547% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | 34.802% |
| HilleVax, Inc. | 344.43 Million USD | 96.584% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -270.435% |
| Tharimmune, Inc. | 10.94 Million USD | -7.478% |
| Genprex, Inc. | 10.67 Million USD | -10.256% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 97.629% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | 87.777% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -384.955% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -182.443% |
| OKYO Pharma Limited | 1.54 Million USD | -663.335% |
| Savara Inc. | 177.56 Million USD | 93.374% |
| Curis, Inc. | 77.28 Million USD | 84.777% |
| Daré Bioscience, Inc. | 21.28 Million USD | 44.719% |
| Carmell Therapeutics Corporation | 63.94 Million USD | 81.602% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -45.498% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | 39.265% |
| BeiGene, Ltd. | 5.8 Billion USD | 99.797% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 3.32% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 99.437% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 96.713% |
| Erasca, Inc. | 395.29 Million USD | 97.024% |
| bluebird bio, Inc. | 619.16 Million USD | 98.1% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -172.126% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.828% |
| DBV Technologies S.A. | 182.98 Million USD | 93.571% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -172.126% |
| Moderna, Inc. | 18.42 Billion USD | 99.936% |
| Vincerx Pharma, Inc. | 18.21 Million USD | 35.417% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -1.545% |
| Molecular Templates, Inc. | 35.38 Million USD | 66.75% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | 91.491% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 98.509% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 96.127% |
| Spruce Biosciences, Inc. | 103.94 Million USD | 88.682% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 97.473% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 96.246% |
| MacroGenics, Inc. | 306.82 Million USD | 96.166% |
| RenovoRx, Inc. | 1.46 Million USD | -702.524% |
| Adicet Bio, Inc. | 207.29 Million USD | 94.325% |
| Prime Medicine, Inc. | 193.85 Million USD | 93.931% |
| Aditxt, Inc. | 44.57 Million USD | 73.608% |
| Adagene Inc. | 115.72 Million USD | 89.834% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -164.133% |
| Quantum-Si incorporated | 298.25 Million USD | 96.055% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 99.209% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -52.611% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 96.651% |
| SciSparc Ltd. | 11.18 Million USD | -5.214% |
| Vericel Corporation | 353.65 Million USD | 96.673% |
| Revelation Biosciences, Inc. | 12.21 Million USD | 3.665% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | 79.324% |
| Generation Bio Co. | 374.75 Million USD | 96.861% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 95.38% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | 92.58% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 96.554% |
| Invivyd, Inc. | 229.18 Million USD | 94.867% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 98.606% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | 3.322% |
| Spero Therapeutics, Inc. | 182.39 Million USD | 93.55% |
| Artelo Biosciences, Inc. | 20.42 Million USD | 42.396% |
| 2seventy bio, Inc. | 565.42 Million USD | 97.919% |
| ADMA Biologics, Inc. | 329.18 Million USD | 96.426% |
| Clene Inc. | 52.34 Million USD | 77.522% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | 79.969% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | 90.943% |
| GeoVax Labs, Inc. | 9.28 Million USD | -26.734% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 98.2% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | 88.645% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | 90.977% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | 87.94% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 83.429% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 95.15% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 99.4% |
| Evaxion Biotech A/S | 12.88 Million USD | 8.718% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 95.332% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 98.437% |
| Trevena, Inc. | 40.6 Million USD | 71.026% |
| Surrozen, Inc. | 46.08 Million USD | 74.468% |
| Tyra Biosciences, Inc. | 225.85 Million USD | 94.791% |
| Cingulate Inc. | 3.49 Million USD | -236.967% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | 29.25% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 82.09% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -0.688% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 95.619% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 98.429% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | 90.655% |
| Clearmind Medicine Inc. | 4.32 Million USD | -172.062% |
| Kronos Bio, Inc. | 213.27 Million USD | 94.484% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | 92.637% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -37.432% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 96.807% |
| Statera Biopharma, Inc. | 21.16 Million USD | 44.425% |
| ImmunityBio, Inc. | 504.45 Million USD | 97.668% |
| Korro Bio, Inc. | 221.66 Million USD | 94.692% |
| Kineta, Inc. | 10.28 Million USD | -14.434% |
| BioVie Inc. | 25.2 Million USD | 53.329% |
| Codexis, Inc. | 136.56 Million USD | 91.385% |
| Celularity Inc. | 143.88 Million USD | 91.824% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 98.148% |
| Celcuity Inc. | 191.21 Million USD | 93.847% |
| Virax Biolabs Group Limited | 5.48 Million USD | -114.534% |
| Cibus, Inc. | 544.41 Million USD | 97.839% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | 90.655% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 42.733% |
| IN8bio, Inc. | 33.7 Million USD | 65.098% |
| Kodiak Sciences Inc. | 479.37 Million USD | 97.546% |
| Annexon, Inc. | 297.67 Million USD | 96.048% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | 93.2% |
| Assembly Biosciences, Inc. | 137.46 Million USD | 91.442% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | 43.958% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 99.607% |
| Eyenovia, Inc. | 28.77 Million USD | 59.12% |
| Puma Biotechnology, Inc. | 230.52 Million USD | 94.896% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -62.86% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | 80.69% |
| Arcellx, Inc. | 825.13 Million USD | 98.574% |
| Cardiff Oncology, Inc. | 81.63 Million USD | 85.589% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 97.455% |
| Regulus Therapeutics Inc. | 30.75 Million USD | 61.74% |
| Moolec Science SA | 24.05 Million USD | 51.084% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 96.206% |
| Geron Corporation | 394.07 Million USD | 97.015% |
| LAVA Therapeutics N.V. | 101.71 Million USD | 88.433% |
| Royalty Pharma plc | 16.38 Billion USD | 99.928% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 98.023% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -68.196% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | 2.181% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | 94.796% |
| Humacyte, Inc. | 128.22 Million USD | 90.825% |
| Structure Therapeutics Inc. | 482.01 Million USD | 97.559% |
| 89bio, Inc. | 596.26 Million USD | 98.027% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 95.334% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -535.946% |
| Genelux Corporation | 27.89 Million USD | 57.821% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | 86.84% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | 94.872% |
| Notable Labs, Ltd. | 19.54 Million USD | 39.793% |
| Liquidia Corporation | 120.43 Million USD | 90.231% |
| Mustang Bio, Inc. | 17.74 Million USD | 33.688% |
| Immunovant, Inc. | 666.71 Million USD | 98.235% |
| Quantum-Si incorporated | 298.25 Million USD | 96.055% |
| Arbutus Biopharma Corporation | 144.4 Million USD | 91.853% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | 78.277% |
| Vera Therapeutics, Inc. | 175.54 Million USD | 93.298% |
| Acasti Pharma Inc. | 73.3 Million USD | 83.95% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -158.442% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 54.952% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 98.781% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -126.69% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | 48.356% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | 77.201% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | 93.489% |
| PepGen Inc. | 143.05 Million USD | 91.776% |
| Moleculin Biotech, Inc. | 38.21 Million USD | 69.215% |
| United Therapeutics Corporation | 7.16 Billion USD | 99.836% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | 38.676% |
| Solid Biosciences Inc. | 164.93 Million USD | 92.867% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -100.349% |
| Immuneering Corporation | 102.58 Million USD | 88.531% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -173.057% |
| Silo Pharma, Inc. | 7.74 Million USD | -51.882% |
| Belite Bio, Inc | 94.64 Million USD | 87.569% |
| XOMA Corporation | 234.3 Million USD | 94.979% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | 94.955% |
| Bionomics Limited | 27.64 Million USD | 57.449% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 97.069% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 89.044% |
| uniQure N.V. | 831.68 Million USD | 98.585% |
| Cassava Sciences, Inc. | 151.66 Million USD | 92.243% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -164.133% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 95.704% |
| Forte Biosciences, Inc. | 38.98 Million USD | 69.818% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -188.845% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | 68.057% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -62.86% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -234.899% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | 0.474% |
| Altimmune, Inc. | 210.64 Million USD | 94.415% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 98.488% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 89.044% |
| Compugen Ltd. | 121.33 Million USD | 90.304% |
| Peak Bio, Inc. | 2.59 Million USD | -353.125% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | 93.173% |
| Benitec Biopharma Inc. | 52.21 Million USD | 77.466% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 96.559% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | 66.166% |
| Zura Bio Limited | 100.84 Million USD | 88.333% |
| PolyPid Ltd. | 15.37 Million USD | 23.465% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | 90.137% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | 66.166% |
| Instil Bio, Inc. | 325.63 Million USD | 96.387% |
| argenx SE | 4.54 Billion USD | 99.741% |
| Immunome, Inc. | 148.54 Million USD | 92.08% |
| Compass Therapeutics, Inc. | 156.87 Million USD | 92.5% |
| Verona Pharma plc | 308.12 Million USD | 96.182% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | 86.471% |
| Shattuck Labs, Inc. | 159.56 Million USD | 92.627% |
| CervoMed Inc. | 9.97 Million USD | -17.974% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | 93.757% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -3.311% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | 93.442% |
| Moolec Science SA | 24.05 Million USD | 51.084% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -92.318% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | 93.197% |
| AnaptysBio, Inc. | 452.38 Million USD | 97.399% |
| Design Therapeutics, Inc. | 289.64 Million USD | 95.938% |
| Leap Therapeutics, Inc. | 72.82 Million USD | 83.845% |
| NeurAxis, Inc. | 509.49 Thousand USD | -2209.136% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -117.147% |
| Lumos Pharma, Inc. | 40.63 Million USD | 71.049% |
| Achilles Therapeutics plc | 161.45 Million USD | 92.713% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | 86.471% |
| 180 Life Sciences Corp. | 5.25 Million USD | -123.691% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | 83.295% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -37.432% |
| Nutriband Inc. | 7.51 Million USD | -56.509% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 95.381% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | 94.097% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | 84.563% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | 79.686% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 97.766% |
| Palisade Bio, Inc. | 14.05 Million USD | 16.275% |
| Tourmaline Bio, Inc. | 210.29 Million USD | 94.405% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 99.194% |
| Neurogene Inc. | 222.57 Million USD | 94.714% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 98.181% |
| AEON Biopharma, Inc. | 6.84 Million USD | -71.877% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 97.403% |
| Sesen Bio, Inc. | 189.17 Million USD | 93.781% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 95.673% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | 14.198% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 98.492% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 95.594% |
| Athira Pharma, Inc. | 160.24 Million USD | 92.658% |
| Vaccinex, Inc. | 3.63 Million USD | -224.015% |
| HCW Biologics Inc. | 28.51 Million USD | 58.739% |
| XOMA Corporation | 234.3 Million USD | 94.979% |
| Nektar Therapeutics | 398.03 Million USD | 97.044% |
| Arvinas, Inc. | 1.3 Billion USD | 99.098% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 30.946% |
| Merus N.V. | 458.49 Million USD | 97.434% |
| Omega Therapeutics, Inc. | 204.36 Million USD | 94.243% |
| Quince Therapeutics, Inc. | 180.2 Million USD | 93.471% |
| Rezolute, Inc. | 132.73 Million USD | 91.137% |
| Clene Inc. | 52.34 Million USD | 77.522% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | 21.167% |
| BeyondSpring Inc. | 24.8 Million USD | 52.576% |
| Synlogic, Inc. | 75.55 Million USD | 84.428% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | 0.818% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -25.641% |
| Peak Bio, Inc. | 2.59 Million USD | -353.125% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | 93.271% |
| Krystal Biotech, Inc. | 818.35 Million USD | 98.562% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 95.107% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 98.379% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -228.891% |
| MannKind Corporation | 475.19 Million USD | 97.524% |
| Ikena Oncology, Inc. | 192.09 Million USD | 93.875% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | 12.031% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | 89.905% |
| Gossamer Bio, Inc. | 311.91 Million USD | 96.228% |
| CohBar, Inc. | 16.36 Million USD | 28.112% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | 66.542% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -60.834% |
| Legend Biotech Corporation | 1.84 Billion USD | 99.364% |
| Mural Oncology plc | 301.74 Million USD | 96.101% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 62.31% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -107.116% |
| Disc Medicine, Inc. | 367.99 Million USD | 96.803% |
| Champions Oncology, Inc. | 26.13 Million USD | 54.979% |
| REGENXBIO Inc. | 573.97 Million USD | 97.95% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -334.44% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 92.379% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | 2.572% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 96.54% |
| Vaxart, Inc. | 91.83 Million USD | 87.188% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | 80.36% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | 92.068% |
| Cellectis S.A. | 334.27 Million USD | 96.48% |
| Longeveron Inc. | 12.17 Million USD | 3.391% |
| Repare Therapeutics Inc. | 253.9 Million USD | 95.366% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 99.64% |
| Inozyme Pharma, Inc. | 200.84 Million USD | 94.142% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 99.437% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -624.0% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 95.764% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | 92.787% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | 91.52% |
| Anixa Biosciences, Inc. | 25.52 Million USD | 53.903% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.948% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 98.98% |
| Revelation Biosciences, Inc. | 12.21 Million USD | 3.665% |
| Veru Inc. | 50.59 Million USD | 76.747% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | 74.173% |
| Cingulate Inc. | 3.49 Million USD | -236.967% |
| Passage Bio, Inc. | 150.54 Million USD | 92.185% |
| Context Therapeutics Inc. | 16.06 Million USD | 26.756% |
| Exicure, Inc. | 11.58 Million USD | -1.598% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 96.871% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | 92.722% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | 32.664% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 96.464% |
| Nuvalent, Inc. | 732.38 Million USD | 98.394% |
| ABVC BioPharma, Inc. | 14.94 Million USD | 21.273% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | 86.863% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | 17.095% |
| OmniAb, Inc. | 401.98 Million USD | 97.073% |
| Anew Medical, Inc. | 19.45 Million USD | 39.53% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | 55.98% |
| Lipocine Inc. | 23 Million USD | 48.85% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | 91.585% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 96.15% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 85.984% |
| G1 Therapeutics, Inc. | 121.54 Million USD | 90.32% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -48.267% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 98.667% |
| Ocugen, Inc. | 64.54 Million USD | 81.773% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | 90.553% |
| Q32 Bio Inc. | 306.11 Million USD | 96.157% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -179.587% |
| Alumis Inc. Common Stock | 89.61 Million USD | 86.871% |
| Equillium, Inc. | 50.53 Million USD | 76.717% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | 84.354% |
| Coya Therapeutics, Inc. | 41.27 Million USD | 71.495% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -591.712% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 54.994% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 81.743% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -215.66% |
| Dominari Holdings Inc. | 57.55 Million USD | 79.56% |
| Edesa Biotech, Inc. | 8.89 Million USD | -32.333% |
| vTv Therapeutics Inc. | 11.01 Million USD | -6.78% |
| Bio-Techne Corporation | 2.81 Billion USD | 99.582% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 98.745% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 98.55% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 95.763% |
| Candel Therapeutics, Inc. | 41.7 Million USD | 71.788% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 98.238% |
| Nkarta, Inc. | 378.88 Million USD | 96.895% |
| BioCardia, Inc. | 2.98 Million USD | -293.873% |
| Iterum Therapeutics plc | 26.25 Million USD | 55.196% |